The FDA has approved a subcutaneous self-injectable for adults with generalized myasthenia gravis who are anti-acetylcholine ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

The Neuromuscular Disease Center has a long history of providing excellent clinical care and research in myasthenia gravis. Myasthenia gravis is a chronic autoimmune disorder that causes muscle ...

Opens in a new tab or window Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the ...

I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue of voluntary muscles.

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

Generalised myasthenia gravis (gMG ... monoclonal antibody therapy that works by blocking a specific protein in the immune system responsible for neuromuscular damage. By preventing the ...

500 attendees in Phoenix, Arizona to educate and inform the MG community. Myasthenia gravis is a rare neuromuscular, autoimmune disease that impacts more than 90,000 individuals in the United ...

Neuromuscular disorders with a specific interest in autoimmune neuromuscular disorders like myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), inflammatory myopathy ...

Generalized myasthenia gravis (gMG) affects most patients ... aminoglycoside and fluoroquinolone antibiotics, and ...

To review: Myasthenia gravis is an autoimmune condition that affects the neuromuscular junction between the nerve and the muscle often referred to as the neuromuscular end plate. In myasthenia ...